- Home
- MYND vs CVM Comparison
MYND vs CVM Comparison
Compare MYND & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | CVM |
|---|---|---|
| Founded | 1998 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 20.4M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MYND | CVM |
|---|---|---|
| Price | $0.39 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 13.7K | ★ 401.0K |
| Earning Date | 05-27-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.28 | $0.89 |
| 52 Week High | $1.15 | $13.48 |
Technical Indicators
Market Signals| Indicator | MYND | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 46.49 | 45.13 |
| Support Level | $0.29 | $0.98 |
| Resistance Level | $0.51 | $1.52 |
| Average True Range (ATR) | 0.04 | 0.13 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 19.79 | 28.17 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.